PlainRecalls
FDA Drug Moderate Class II Ongoing

Rifampin Capsules, USP, 300 mg, a) 30-count bottle (NDC 61748-018-30), b) 60-count bottle (NDC 61748-018-60), c) 100-count bottle (NDC 61748-018-01), Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031.

Reported: October 5, 2022 Initiated: September 21, 2022 #D-1548-2022

Product Description

Rifampin Capsules, USP, 300 mg, a) 30-count bottle (NDC 61748-018-30), b) 60-count bottle (NDC 61748-018-60), c) 100-count bottle (NDC 61748-018-01), Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031.

Reason for Recall

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Details

Recalling Firm
Akorn, Inc.
Units Affected
177,439 bottles
Distribution
USA Nationwide and Puerto Rico
Location
Gurnee, IL

Frequently Asked Questions

What product was recalled?
Rifampin Capsules, USP, 300 mg, a) 30-count bottle (NDC 61748-018-30), b) 60-count bottle (NDC 61748-018-60), c) 100-count bottle (NDC 61748-018-01), Rx only, Distributed by: Akorn Operating Company, LLC, Gurnee, IL 60031.. Recalled by Akorn, Inc.. Units affected: 177,439 bottles.
Why was this product recalled?
Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).
Which agency issued this recall?
This recall was issued by the FDA Drug on October 5, 2022. Severity: Moderate. Recall number: D-1548-2022.